78699d1d-aa39-473a-b3ea-24164d3a443c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.660
- MYC_TARGETS_V1+0.590
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V2+0.510
- MTORC1_SIGNALING+0.400
- DNA_REPAIR+0.380
- OXIDATIVE_PHOSPHORYLATION+0.340
- INTERFERON_ALPHA_RESPONSE+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.290
- MITOTIC_SPINDLE+0.240
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- UV_RESPONSE_DN-0.350
- MYOGENESIS-0.340
- WNT_BETA_CATENIN_SIGNALING-0.300
- HEDGEHOG_SIGNALING-0.280
- APICAL_JUNCTION-0.230
- ANGIOGENESIS-0.220
- COAGULATION-0.210
- BILE_ACID_METABOLISM-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650153 | — | — | 0.851 |
| 2 | TCGA-XF-A9T6-01A-11R-A42T-07 | — | — | 0.851 |
| 3 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.851 |
| 4 | TCGA-T3-A92N-01A-11R-A39I-07 | — | — | 0.844 |
| 5 | SRR8518289 | — | E | 0.841 |
| 6 | SRR6013511 | — | cohortSQ1 | 0.840 |
| 7 | TCGA-HD-7832-01A-11R-2132-07 | — | — | 0.839 |
| 8 | TCGA-DK-A1A6-01A-11R-A13Y-07 | — | — | 0.838 |
| 9 | 04e3aeba-c9bd-483d-9484-5ecc0e64a054 | — | — | 0.832 |
| 10 | SRR6013495 | — | cohortA1 | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.660 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |